Solid oral dosage forms of valsartan

Patent 6858228 Issued on February 22, 2005. Estimated Expiration Date:

September 20, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3200039

Divisible tablet having controlled and delayed release of the active substance
Patent #: 4353887
Issued on: 10/12/1982
Inventor: Hess , et al.

Acyl compounds
Patent #: 5399578
Issued on: 03/21/1995
Inventor: Buhlmayer, et al.

Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
Patent #: 5464854
Issued on: 11/07/1995
Inventor: dePadova

Readily available konjac glucomannan as a sustained release excipient
Patent #: 5486364
Issued on: 01/23/1996
Inventor: King, et al.

Use of an angiotensin II antagonist and a benzofuran derivative in the treatment of cardiovascular complaints
Patent #: 6218414
Issued on: 04/17/2001
Inventor: Nisato

Solid oral dosage forms of valsartan
Patent #: 6294197
Issued on: 09/25/2001
Inventor: Wagner, et al.

Solid oral dosage forms of valsartan Patent #: 6485745
Issued on: 11/26/2002
Inventor: Wagner, et al.

Inventors

Assignee

Novartis AG

Application

No. 10251009 filed on 09/20/2002

US Classes:

424/465, With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.)424/464, Tablets, lozenges, or pills424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)514/223.5, With additional active ingredient514/223.2, 1,2,4 - Benzothiadiazine - 1,1 - dioxides (including hydrogenated)514/222.8, Polycyclo ring system having the six-membered hetero ring as one of the cyclos514/381, Tetrazoles (including hydrogenated)424/488, Polysaccharides (e.g., cellulose, etc.)514/382Additional chalcogen containing hetero ring

Examiners

Primary: Page, Thurman K.
Assistant: Di Nola-Baron, Liliana

Attorney, Agent or Firm

Ferraro; Gregory D.

Foreign Patent References

2421 273 DE 11/01/1974
11 490 EP 05/01/1980
70 127 EP 01/01/1983
396 335 EP 11/01/1990
9315732 WO 08/01/1993
94 09778 WO 05/01/1994
95 24901 WO 09/01/1995
95 28927 WO 11/01/1995
95 29674 WO 11/01/1995

International Class

A61K009/20

Abstract

The present invention is concerned with solid oral dosage forms of comprising a) an active agent selected from valsartan and optionally HCTZ, and b) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.

Other References

“Hydrochlorothiazide”—Martindale 89 pp. 991-993.
“Innovatives Antihypertensives,” Therapiewoche 36, pp. 1982-1985 (1996).
Chemical Abstracts 124:220073 (1996).
DIALOG: Derwent Drug File—Abstract AN:96-09445 (1996).
DIALOG: Drug Data Report—Abstract AN 185987 (1992).
DIALOG: JICST EPlus—Abstract AN:96A0157433 (1995).
EMBASE: Abstract 96015489 (1995).
EMBASE: Abstract 96-374183 (1996).
EMBASE: Abstract AN-97-027003 (1997).
Fujimara Y. et al., “Antihypertensive effect of a combination of Valsartan . . . ”, Yakuri To Chiryo, vol. 23, No. 12, 1995, pp. 3241-3247.
Grun, A. et al., “A comparison of the efficacy and tolerability . . . ”,European Heart Journal, vol. 161, No. Sup. (1995) p. 61.
Lachman, L. et al., “The Theory and Practice of Industrial Pharmacy,” Lea & Febiger, 1986, pp. 318-320.
Markham, A., et al., “Valsartan: a review of its pharmacology and therapeutic use . . . ,” DRUGS, vol. 54, No. 2, (1997) pp. 299-311.
TOXLIT: Abstract AN-96:69983 (1995).
Fujimura et al., “Antihypertensive Effect of a Combination of Valsartan and Hydroclorothiazide, Nifedipine or Propranolol in Spontaneously Hypertensive Rats,” Japan Pharmacol Ther, vol. 23(12), pp. 3241-3247 (1995). English Translation Included.